WST Stock Analysis — West Pharmaceutical Services
Sector: Healthcare
AI Verdict
You're paying up for a narrative of durable growth and customer lock-in at 36.0x forward earnings—reasonable if the moat holds, but the current price leaves little margin for error.
Competitive Moat
West Pharmaceutical Services dominates the market for specialized packaging and delivery components for injectable drugs, supplying proprietary stoppers, seals, and syringes that are critical for pharma clients' regulatory compliance. Its moat comes from deep integration into customers' drug manufacturing processes and high switching costs due to regulatory requalification requirements.
Summary
WST is notable for its high-margin, mission-critical drug packaging components that are deeply embedded in pharma supply chains.
Where It Stands
Shares are up 40.68% over the past year with an RSI of 72.6 (overbought) and trade at 36.0x forward earnings, well above the healthcare sector median of 22x.
Key Metrics
- RSI: 72.6 — Overbought
- Trailing P/E: 44.3x
- Forward P/E: 36.0x
- PEG Ratio: 1.82
- Earnings Growth: +0.2%
- Revenue Growth: +0.1%
- Market Cap: $24.4B
- Dividend Yield: 0.00%
- 1-Year Return: 40.68%
- 52-Week High: $386.00
- 52-Week Low: $223.83
Analyst Consensus
21 Buy · 2 Hold · 0 Sell (23 analysts)
Bull Case
Analysts expect 23.1% EPS growth next year, so even at a 36.0x forward P/E, you're paying a fair multiple for a business with entrenched customer relationships and double-digit revenue growth (12.4% YoY).
Bear Case
With an RSI of 72.6 and a trailing P/E of 44.3x, a return to the sector median P/E of 22x would mean a nearly 50% valuation reset if growth stumbles.
Catalyst to Watch
Watch for major new drug approvals or contract wins, as these can lock in multi-year revenue streams and justify the premium multiple.